Medicine and Health Sciences Commons^™

Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancers And Associations With Clinical Factors, A. Clements, D. Engle, D. Shelton, T. Neff, S. Park, D. Bender, A. Ahmed, Koen De Geest, A. Button, J. Engelhardt, Michael Goodheart

Koen De Geest

No abstract provided.

Metastatic Choriocarcinoma To The Lung Coexistent With A Viable Pregnancy, A. Ahmed, Koen De Geest, T. Van Natta, J. Sorosky

Koen De Geest

No abstract provided.

Gog 175: A Randomized Phase Iii Trial Of Iv Carboplatin (Auc 6) And Paclitaxel 175 Mg/M(2) Q 21 Days X 3 Courses Plus Low-Dose Paclitaxel 40 Mg/M(2)/Wk Versus Iv Carboplatin (Auc 6) And Paclitaxel 175 Mg/M(2) Q 21 Days X 3 Courses Plus Observation In Patients With Early-Stage Ovarian Carcinoma, R. Mannel, M. Brady, E. Kohn, P. Hanjani, M. Hiura, R. Lee, Koen De Geest, D. Cohn, B. Monk, H. Michael

Koen De Geest

No abstract provided.

Lymphoid Enhancing Factor 1 (Lef-1) Overexpression In Epithelial Ovarian, Fallopian Tube And Peritoneal Cancer And Associations With Clinical Factors, Aine Clements, David Engle, Dawne Shelton, Traci Neff, Soo Park, David Bender, Amina Ahmed, Koen De Geest, Anna Button, John F. Engelhardt, Michael Goodheart

Koen De Geest

Lef-1 mRNA levels were statistically elevated in cases of ovarian, fallopian tube or peritoneal cancer when compared to non-cancerous controls. Among cancer cases, levels of Lef-1 were statistically different between stage and histology. Lef-1 overexpression may be predictive of poor overall survival. These findings suggest that Lef-1 overexpression may contribute to ovarian, fallopian tube and peritoneal carcinogenesis, and that further investigation is warranted.

The Relationship Between Vascularity, P53 Gene Mutations And Distant Metastatic Disease In Epithelial Ovarian Carcinoma, Janna Girardi, Megan Samuelson, Anna Button, Koen De Geest, David P. Bender, Amina Ahmed, Michael Goodheart

Koen De Geest

Mutations of the p53 tumor suppressor gene are associated with large differences (>7 vessels/HPF) in Microvessel density (MVD) counts between primary and metastatic tumor sites in patients with epithelial ovarian cancer. These data are consistent with models demonstrating p53 mutation functions directly to influence angiogenesis. This information supports continued therapy and research involving angiogenesis inhibitors in patients with ovarian cancer, especially in the setting of increased differences in MVD between primary and metastatic sites.

Zmiz1 Is Overexpressed In Epithelial Ovarian Cancer And Associated With P53 Gene Mutations, Niyati J. Nadkarni, Laura M. Rogers, Megan Samuelson, Traci Neff, David P. Bender, Amina Ahmed, Koen De Geest, Anna Button, Adam Dupuy, Michael Goodheart

Koen De Geest

Zmiz1 staining is elevated in patients with epithelial ovarian cancer. Tumors that are Zmiz1 positive are associated with mutations of the p53 gene. Zmiz1 overexpression may be associated with decreased survival in patients with epithelial ovarian cancer. Additional studies are needed to more clearly determine the role of Zmiz1 in patients with epithelial ovarian cancer.

Phase Ii Clinical Trial Of Ixabepilone In Patients With Recurrent Or Persistent Platinum- And Taxane-Resistant Ovarian Or Primary Peritoneal Cancer: A Gynecologic Oncology Group Study, Koen De Geest, John Blessing, Robert Morris, S. Diane Yamada, Bradley Monk, Susan Zweizig, Daniela Matei, Carolyn Muller, William Richards

Koen De Geest

PURPOSE Ixabepilone (BMS-247550) is a microtubule-stabilizing epothilone B analog with activity in taxane-resistant metastatic breast cancer. The Gynecologic Oncology Group conducted a phase II evaluation of the efficacy and safety of ixabepilone in patients with recurrent or persistent platinum- and taxane-resistant primary ovarian or peritoneal carcinoma. PATIENTS AND METHODS Patients with measurable platinum- and taxane-resistant ovarian or peritoneal carcinoma, defined as progression during or within 6 months of one prior course of treatment with each agent, received intravenous ixabepilone 20 mg/m(2) administered over 1 hour on days 1, 8, and 15 of a 28-day cycle. RESULTS Of 51 patients entered, …

Endometrial Cancer: Reviving Progesterone Therapy In The Molecular Age, S. Yang, K. Thiel, Koen De Geest, Kimberly Leslie

Koen De Geest

Endometrial cancer is the most common gynecologic malignancy and represents a major health concern because overall five-year survival rates have not improved in the last three decades. A great deal of research demonstrates that the endometrium is extremely sensitive to hormones, and a shift in the estrogen:progesterone balance is the major cause for the development of endometrial cancer. Progestin-based therapy has proven effective in a subset of patients, particularly in situations where expression of progesterone receptor (PR) is maintained. However, this approach is not routinely used in the clinic in the U.S. for several reasons. For example, many endometrial tumors …

Preservation Of Immune Function In Cervical Cancer Patients During Chemoradiation Using A Novel Integrative Approach., Susan Lutgendorf, Elizabeth Mullen-Houser, Daniel Russell, Koen De Geest, Geraldine Jacobson, Laura Hart, David Bender, Barrie Anderson, Thomas Buekers, Michael Goodheart, Michael Antoni, Anil Sood, David Lubaroff

Koen De Geest

Patients receiving chemoradiation for cervical cancer are at risk for distress, chemoradiation-related side-effects, and immunosuppression. This prospective randomized clinical trial examined effects of a complementary therapy, Healing Touch (HT), versus relaxation training (RT) and usual care (UC) for (1) supporting cellular immunity, (2) improving mood and quality of life (QOL), and (3) reducing treatment-associated toxicities and treatment delay in cervical cancer patients receiving chemoradiation. Sixty women with stages IB1 to IVA cervical cancer were randomly assigned to receive UC or 4 ×/weekly individual sessions of either HT or RT immediately following radiation during their 6-week chemoradiation treatment. Patients completed psychosocial …

Diurnal Cortisol Dysregulation, Functional Disability, And Depression In Women With Ovarian Cancer., Aliza Weinrib, Sandra Sephton, Koen De Geest, Frank Penedo, David Bender, Bridget Zimmerman, Clemens Kirschbaum, Anil Sood, David Lubaroff, Susan Lutgendorf

Koen De Geest

BACKGROUND: Multiple alterations in circadian rhythms have been observed in cancer patients, including the diurnal rhythm of the adrenal hormone cortisol. Diurnal cortisol alterations have been associated with cancer-related physiological processes as well as psychological stress. Here we investigate alterations in diurnal cortisol rhythm in ovarian cancer patients, and potential links with depression, life stress, and functional disability.

METHODS: Women (n = 177) with suspected ovarian cancer completed questionnaires and collected salivary cortisol 3× daily for 3 consecutive days before surgery. One hundred women were subsequently diagnosed with ovarian cancer and 77 with benign disease. In addition, healthy women (n …

Primary Fallopian Tube Cancer - 30 Years Experience At The University Of Iowa, Alireza Shamshirsaz, Michael Goodheart, Gideon Zamba, David Bender, Thomas Buekers, Koen De Geest

Koen De Geest

No abstract provided.

A Single-Institution Evaluation Of Factors Important In Fallopian Tube Carcinoma Recurrence And Survival., Alireza Shamshirsaz, Thomas Buekers, Koen De Geest, David Bender, Gideon Zamba, Michael Goodheart

Koen De Geest

OBJECTIVE: The aim of this study was to identify prognostic factors and markers that influence clinical outcomes in patients with primary fallopian tube carcinoma at a single tertiary health care center. These prognostic factors may be of clinical importance and can subsequently be included in future clinical trials. MATERIALS AND METHODS: A retrospective review of our Tumor Registry and Gynecologic Oncology database was conducted to include any patients with a diagnosis of fallopian tube carcinoma between the years 1994 and 2005. We identified clinicopathological data to evaluate factors important in recurrence, disease-specific and overall survival. Kaplan-Meier curves were generated, and …

The Role Of Lymphoid-Enhancing Factor 1 (Lef-1) In Endometrial Gland Morphogenesis, Michael Goodheart, T. Neff, S. Yeun-Park, X. Liu, W. Xie, Koen De Geest, David Bender, T. Buekers, J. Engelhardt

Koen De Geest

No abstract provided.

Intraoperative Autologous Blood Transfusion Use During Radical Hysterectomy For Cervical Cancer: Long-Term Follow-Up Of A Prospective Trial, David Engle, Joseph Connor, Peter Morris, David Bender, Koen De Geest, Amina Ahmed, Michael Goodheart

Koen De Geest

No abstract provided.

Microvessel Density And P53 Mutations In Advanced-Stage Epithelial Ovarian Cancer, Niyati Nadkarni, Koen De Geest, Traci Neff, Barry De Young, David Bender, Amina Ahmed, Brian Smith, Anna Button, Michael Goodheart

Koen De Geest

No abstract provided.

Sleep Disturbance, Cytokines, And Fatigue In Women With Ovarian Cancer., Lauren Clevenger, Andrew Schrepf, Desire Christensen, Koen De Geest, David Bender, Amina Ahmed, Michael Goodheart, Frank Penedo, David Lubaroff, Anil Sood, Susan Lutgendorf

Koen De Geest

Pro-inflammatory cytokines, such as interleukin-6 (IL-6), have been implicated in the underlying processes contributing to sleep regulation and fatigue. Despite evidence for sleep difficulties, fatigue, and elevations in IL-6 among women with ovarian cancer, the association between these symptoms and IL-6 has not been investigated. To address this knowledge gap, we examined relationships between sleep disturbance, fatigue, and plasma IL-6 in 136 women with ovarian cancer prior to surgery. These relationships were also examined in 63 of these women who were disease-free and not receiving chemotherapy one year post-diagnosis. At both time-points, higher levels of IL-6 were significantly associated with …

Social Isolation Is Associated With Elevated Tumor Norepinephrine In Ovarian Carcinoma Patients., Susan Lutgendorf, Koen De Geest, Laila Dahmoush, Donna Farley, Frank Penedo, David Bender, Michael Goodheart, Thomas Buekers, Luis Mendez, Gina Krueger, Lauren Clevenger, David Lubaroff, Anil Sood, Steve Cole

Koen De Geest

Noradrenergic pathways have been implicated in growth and progression of ovarian cancer. Intratumoral norepinephrine (NE) has been shown to increase with stress in an animal cancer model, but little is known regarding how tumor NE varies with disease stage and with biobehavioral factors in ovarian cancer patients. This study examined relationships between pre-surgical measures of social support, depressed mood, perceived stress, anxiety, tumor histology and tumor catecholamine (NE and epinephrine [E]) levels among 68 ovarian cancer patients. We also examined whether associations observed between biobehavioral measures and tumor catecholamines extended to other compartments. Higher NE levels were found in advanced …

A Phase Ii Study Of Docetaxel In Paclitaxel-Resistant Ovarian And Peritoneal Carcinoma: A Gynecologic Oncology Group Study, Peter Rose, John Blessing, Harrison Ball, James Hoffman, David Warshal, Koen Degeest, David Moore

Koen De Geest

OBJECTIVES: Docetaxel is an inhibitor of microtubule depolymerization and has demonstrated activity in paclitaxel-resistant breast cancer and gynecologic cancer. The Gynecologic Oncology Group (GOG) conducted a study of docetaxel in paclitaxel-resistant ovarian and peritoneal carcinoma to determine its activity, and nature and degree of toxicity, in this cohort of patients.

METHODS: Patients with platinum- and paclitaxel-resistant ovarian or peritoneal carcinoma, defined as progression while on or within 6 months of therapy, were eligible if they had measurable disease and had not received more than one chemotherapy regimen. Docetaxel at a dose of 100 mg/m(2) was administered iv over 1 h …